Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Mirikizumab in Healthy Chinese Subjects
NCT04137380Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mirikizumab in ulcerative colitis (UC) and Crohn's disease (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants With One or More Drug-Related Treatment-Emergent Adverse Events and Visual Analog Scale (VAS) Pain Score for Subcutaneous Injection Site. Started Dec 2019; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT04137380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04137380.